SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
F O R M 6-K
REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16
UNDER THE SECURITIES EXCHANGE ACT OF 1934
For the month of July 2025
TRINITY BIOTECH PLC
(Name of Registrant)
IDA Business Park
Bray, Co. Wicklow, Ireland
(Address of Principal Executive Office)
Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F.
Form 20-F ☒ Form 40-F ☐
This Form 6-K is being incorporated by reference into our Registration Statements on Form F-3 (File Nos. 333-286020, 333-267160, 333-280391, 333-283273) and Form S-8 (File Nos. 333-182279, 333-195232
and 333-253070).
EXPLANATORY NOTE
On July 1, 2025, the Company issued a press release announcing that it had reached a profitability inflection point, marking a major
milestone in its strategic turnaround. It also announced its financial results for the fiscal quarter ended March 31, 2025. A copy of the press release is filed herewith as Exhibit 99.1.
EXHIBIT INDEX
|
Exhibit
|
|
Description
|
|
|
|
|
|
99.1
|
|
Trinity Biotech Reaches Profitability Inflection Point, Marking Major Milestone in Strategic Turnaround.
|
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.
| |
TRINITY BIOTECH PLC
|
|
| |
|
Trinity Biotech plc
|
|
| |
|
(Registrant)
|
|
| |
|
|
|
| |
By:
|
/s/ Susan O’Connor
|
|
| |
|
Susan O’Connor
|
|
| |
|
Interim Chief Financial Officer
|
|
Date: July 01, 2025
